Dhawaan dhawaan, natiijooyinka daraasad cusub, oo lagu magacaabo Empagliflozin Cardiovascular Event Wareegga ee Nooca 2-aad ee Diabetes Mellitus Bukaan-socodka (EMPA-REG OUTCOME), ayaa lagu daabacay Wargayska New England Journal of Medicine . Natiijada ugu dambaysay, natiijooyinka waxaa lagu soo bandhigay Ururka Midowga Yurub ee Daraasada Sonkorowga (EASD) 2015 oo lagu kulmay wareegyo badan oo ka mid ah taxadar qaali ah oo ka yimid qareeno badan oo ku takhasusay imaanshaha.
Inkasta oo tijaabadani ay kaliya baratay bukaanada leh sonkorowga nooca 2, waxaan rumeysanahay in natiijooyinkani ay noqon karaan bedelaade loogu talagalay maaraynta macaanka guud ahaan. Daraasadani ma muujin oo keliya in daawada, Empagliflozin, ay tahay mid amaan ah laakiin waxay sidoo kale muujisay in ay leedahay suurtogalnimada in si dhakhso ah loo yareeyo natiijooyinka wadnaha iyo joogtada ah. Muhiimadda tani ma noqon karto mid laga xumaado illaa qiyaastii 50% dhimashooyinka caalamka oo dhan ka yimaada sokorowga ayaa toos u ah cudurada wadnaha. Ilaa illaa daraasadani, ma aha daaweyn macaan oo keliya oo loo arkay in la yareeyo khatarta wadnaha iyo guud ahaan dhimashada. Taa baddalkeeda, daawooyinka waaweyn ee daawooyinka loo isticmaalo si loo daaweeyo cudurka macaanka ayaa kaliya lagu muujiyay in ay yareeyaan dhibaatooyinka dheellitirka micnaha; kuwaas oo ah dhibaatooyinka mustaqbalka fog ee sonkorowga ee saameeya xididdada dhiigga yar. Noocyadaasi waxay kudartaa retinopathy (waxyeelo gaarsiisan retina), nephropathy (waxyeelada kelyaha), iyo neuropathy (waxyeelo u dareemayaasha).
Empagliflozin waa soodhawritir sodium-glucose (SLGT-2) inhibitor ah. Noocaan daawo ayaa hoos u dhigaya heerarka gulukooska dhiigga oo sareeya iyada oo xannibaya gaadiidleyda, si cad loogu magacaabo SGLT-2s, taas oo horseedi karta dib u soo noqoshada gulukoosta kelyaha ilaa dhiigga. Taasi waxay sababtay sonkorta, sonkorta laga yaabo in ay u horseedi karto akhrinta gulukooska dhiigga sareeya halkii uu ka sii deyn lahaa musqusha.
Marka laga soo tago faa'iidada akhrinta A1C-ka ee hemoglobin , daawooyinkan ayaa sidoo kale keena miisaan weyn oo hoos u dhaca cadaadiska dhiigga.
Cudurka SGLT-2 wuxuu ahaa FDA oo la oggolaaday nooca 2aad ee sonkorowga horraantii sanadka 2013 waxaana ku jira daawooyinka sida Canagliflozin (Invokana), Dapagliflozin (Farxiga), iyo Empagliflozin (Jardiance).
Iyadoo daawooyinkaan aan weli la ogolaanin nooca 1aad ee sonkorowga, daraasado yaryar ayaa muujiyey in SGLT-2 inhibitorku ay sidoo kale hagaajiyaan xakamaynta glycemic iyo natiijada miisaanka culus ee bukaanka qaba nooca 1aad ee sonkorowga. In kastoo la'aanta caddaynta FDA ee calaamadahan, dad badan oo ku takhasusay indhaha ayaa isticmaalaya daawada SGLT-2 si loogu daweeyo bukaankooda qaba sonkor nooca 1 ah.
Daraasada EMPA-REG OUTCOME, natiijada ugu weyn ee ka soo baxday wadnaha ayaa la yareeyay 14%. Xogta aad u xiiso badani waxay ahayd in dhimashada wadnaha, dhimashada oo dhan iyo cusbitaaleynta wadnaha oo shaqeyn waayay ayaa dhammaantood hoos u dhacay 30%. Cabbirka weyn ee daraasaddan (in ka badan 7000 oo bukaan ah!) Waxay fursad u heleysaa inay sabab u tahay natiijooyinka cajiibka ah.
Sidoo kale qasab waxay ahayd in la ogaado in dhimashada dhimashada iyo isbitaalnimadu ay bilawday horraantii daraasadda. Tani waxay muujinaysaa in hoos u dhaca natiijooyinka aysan u badnayn inay sabab u tahay heerarka sonkorta, akhriska cadaadiska dhiigga ama miisaan lumis, maadaama saameynta isbeddelladani la filayo inay muujiyaan muddada dheer.
Sidaa daraadeed, waxaa jira wax wali qarsoodi ah oo laga yaabo in ay isbedbeddelaan taasoo keenta isbeddel deg-deg ah oo ku yimaada cilmi-nafsiga.
Su'aalaha ugu caansan ee lagu caddeeyey cilmi-baaristan ayaa ah in tani ay tahay saameyn fasalka sida dhammaan SGLT-2 inhibitorku waxay soo saaraan xogta natiijada wadnaha ee wadnaha ee tijaabada ama saameyn ku leh Empagliflozin? Tani waxay noqoneysaa in la go'aamiyo, laakiin waxaan dareemayaa kalsooni in daraasadaha la midka ah ee Canagliflozin iyo Dapagliflozin ayan ka fogaan karin. Joogso!